Genomic strategy anticipates drug safety signals before clinical harm emerges

A study published in PLOS Genetics by Brian R. Ferolito, Andrea R. V. R. Horimoto, and colleagues from the Million Veteran Program, the Broad Institute, and collaborating European institutions describes a genomic-led strategy for anticipating adverse drug effects before they manifest in clinical populations.

Safety-related failures account for roughly 25 per cent of drug development attrition. The framework integrates genome-wide association data, pharmacogenomic signals, and target gene biology to generate early-stage indicators of potential off-target or toxic effects. The authors applied the approach across multiple drug classes and found it could surface safety-relevant signals that preceded known post-marketing withdrawals or black-box warning updates in several cases.

The method uses publicly available GWAS summary statistics and databases such as ChEMBL alongside target-gene mapping to flag variant–drug interactions that may predict adverse outcomes. It does not require proprietary biobank data at the point of application, though the validation drew heavily on the Million Veteran Program cohort.

The study is relevant to researchers in pharmacogenomics and drug development, as well as computational geneticists building variant-to-function pipelines. It adds to a growing body of work arguing that genetic evidence, when integrated systematically at the target-identification stage, can reduce late-stage safety attrition — a recurring cost driver in pharmaceutical research.